

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4411120

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RICHARD W. CHILDS	11/17/2015
MATTIAS C.V. CARLSTEN	11/18/2015
RECEIVING PARTY DATA	
Name:	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Street Address:	6011 EXECUTIVE BOULEVARD, SUITE 325, MSC 7660
Internal Address:	OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH
City:	BETHESDA
State/Country:	MARYLAND
Postal Code:	20892-7660
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15525921
CORRESPONDENCE DATA	
Fax Number:	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	503-595-5300
Email:	susan.graf@klarquist.com
Correspondent Name:	SUSAN W. GRAF/KLARQUIST SPARKMAN, LLP
Address Line 1:	121 SW SALMON STREET
Address Line 2:	SUITE 1600
Address Line 4:	PORTLAND, OREGON 97204
ATTORNEY DOCKET NUMBER:	4239-95108-03
NAME OF SUBMITTER:	SUSAN W. GRAF, PH.D.
SIGNATURE:	/Susan W. Graf/
DATE SIGNED:	05/12/2017
Total Attachments: 3	
source=Assignment#page1.tif	

source=Assignment#page2.tif

source=Assignment#page3.tif

**ASSIGNMENT FOR NIH/FDA/CDC INVENTIONS AIA
(NIH OR FDA OR CDC CO-INVENTORS ONLY)**

WHEREAS, we, Richard W. Childs and Mattias C.V. Carlsten, employees of the National Institutes of Health, are each employed by a component of the United States Department of Health and Human Services having an address at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, MD 20892-7660, and have made certain inventions as described and claimed in:

U.S. Provisional Patent Application No. 62/079,975, filed on November 14, 2015, entitled "NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORS," and

PCT Patent Application No. PCT/US2015/060646, filed on November 13, 2015, entitled "NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORS,"

both of which applications are collectively referred to herein as "**The Patent Applications**"; and

WHEREAS, we are the inventors named in **The Patent Applications**; and

WHEREAS, the inventions described and claimed in **The Patent Applications** were made under conditions such as to entitle **THE UNITED STATES OF AMERICA**, as represented by the Secretary, Department of Health and Human Services [hereinafter **THE GOVERNMENT**] under Executive Order 10096 and its amendments, 35 U.S.C. §§200-201, §§206-207, and §210 and 37 C.F.R. Part 501 to the entire right, title, and interest in such inventions; and

WHEREAS, THE GOVERNMENT is desirous of acquiring all domestic and foreign right, title, and interest in the inventions described and claimed in **The Patent Applications**;

NOW, THEREFORE, having the legal obligation to assign our right, title and interest in the inventions described and claimed in **The Patent Applications** to **THE GOVERNMENT**, having a place of business at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, MSC 7660, Bethesda, MD 20892-7660 and for consideration, the receipt and sufficiency of which are hereby acknowledged, we hereby assign and transfer to **THE GOVERNMENT**:

the entire right, title, and interest in and to any and all inventions described and claimed in **The Patent Applications** and any and all Letters Patent which may be granted thereon, and any and all continuations, divisions, reissues or extensions thereof; and

all rights to claim priority on the basis of **The Patent Applications** including but not limited to applications filed through the provisions of the Patent Cooperation Treaty ("**PCT Applications**"); and



all applications for Letters Patent that may be filed for any and all inventions described and claimed in **The Patent Applications** that may be filed in any foreign country and all Letters

Patent that may be granted thereon in any foreign country and all extensions, renewals, and reissues thereof; and

any and all such Letters Patent as may be granted in the United States or any foreign country to be held by **THE GOVERNMENT** to the end of the term for which the same would have been held by the inventors had this assignment not been made.

We further agree to make, execute, and deliver to **THE GOVERNMENT**, upon request, any and all papers, documents, affidavits, or other instruments that may be necessary in the prosecution of any application or applications for improvements or reissues of Letters Patent, and to assist **THE GOVERNMENT** in every way as may be requested in protecting said invention.

IN WITNESS WHEREOF we subscribe our hands and seals on the dates shown below:

Inventor: Richard W. Childs	
Date <u>11/17/15</u>	 Inventor Signature
County of <u>Montgomery</u>	
State of <u>Maryland</u>	
Subscribed and sworn to before me this <u>17</u> day of <u>November</u> , <u>2015</u> .	
Seal	
	Notary Signature: <u>Ann Dorsey</u>
	Notary Public for the State of: <u>Maryland</u>
	My Commission Expires: <u>August 15, 2018</u>

Inventor: Mattias C.V. Carlsten	
Date <u>November 18, 2015</u>	<u>[Signature]</u> Inventor Signature
Witnessed by: <u>[Signature]</u>	
Name (Print): <u>Jonas Holmsten</u>	
Address: <u>Gökvägen 5</u>	
<u>16772 Bromma</u>	
Date: <u>November 18 2015</u>	
Witnessed by: <u>[Signature]</u>	
Name (Print): <u>NONDIA SUREK</u>	
Address: <u>KUNGLAGEN 4A</u>	
<u>118 63 STOCKHOLM SWEDEN</u>	
Date: <u>November 18, 2015</u>	